247923-40-6

Usage

Uses

Used in Organic Synthesis:
(1S,2S)-(-)-N-(2,4,6-TRIMETHYLPHENYLSULFONYL)-1,2-DIPHENYLETHANE-1,2-DIAMINE is used as a reagent in organic synthesis for the production of chiral ligands and catalysts. Its unique structure and properties make it an essential component in the creation of enantiopure compounds, which are crucial for various applications in the pharmaceutical and chemical industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (1S,2S)-(-)-N-(2,4,6-TRIMETHYLPHENYLSULFONYL)-1,2-DIPHENYLETHANE-1,2-DIAMINE is used as a building block for the preparation of chiral auxiliaries and pharmaceutical intermediates. Its specific orientation of atoms and unique properties contribute to the development of new drugs with improved efficacy and selectivity.
Used in Chiral Auxiliaries and Catalysts Production:
(1S,2S)-(-)-N-(2,4,6-TRIMETHYLPHENYLSULFONYL)-1,2-DIPHENYLETHANE-1,2-DIAMINE is used as a key component in the production of chiral auxiliaries and catalysts. These are essential tools in asymmetric synthesis, which allows for the selective formation of one enantiomer over another, leading to the creation of enantiopure compounds with specific biological activities.

Upstream product

• 773-64-8 2-mesitylenesulphonyl chloride 
• 29841-69-8 (S,S)-1,2-diphenyl-1,2-diaminoethane 

Downstream Products

• 1295509-40-8 C₄₄H₄₉N₅O₃S₂ 

Relevant academic research and scientific papers

Catalytic asymmetric Michael addition with curcumin derivative

Catalytic asymmetric Michael additions with curcumin derivatives were achieved by a new series of tertiary amine-thiourea organocatalysts to afford the Michael adducts in high yields and excellent enantioselectivities.

Ir(III) complexes of diamine ligands for asymmetric ketone hydrogenation

The use of a combination of IrCl3 with a series of ligands derived from the C2-symmetric diamine diphenylethanediamine (DPEN) forms a catalyst capable of the asymmetric hydrogenation of ketones in up to 85% ee.

Preparation of mono-N-sulphonylated diamines

The present invention relates to a process for preparing mono-N-sulphonylated diamines by reacting diamines with sulphonyl halides in the presence of water, base and organic solvents.

Process for preparing mono-N-sulfonylated diamines

Production of mono-N-sulfonylated diamine compounds comprises reaction of a diamine compound with a sulfonyl halide in the presence of water, organic solvent and a base. Production of mono-N-sulfonylated diamine compounds (I) of formula (1) comprises reaction of a diamine compound of formula (2) with a sulfonyl halide of formula (3) in the presence of water, organic solvent and a base. R3SO2X (3) R1 and R2 = 1-20C alkyl, 4-15C aryl, 5-16C arylalkyl or R1 and R2 together form a 3-12C alkylene; R3 = 1-20C alkyl, optionally fluorinated or 4-15C aryl; and X = F, Cl, Br or I. Independent claims are also included for the following: (1) solutions (II) containing the mono-N-sulfonylated diamine compounds (I) prepared by the process followed by at least partial removal of water; and (2) catalysts (III) prepared from the solutions (II) by reaction with organometallic compounds of formula (4). (MXn(R4))2 (4) M = Ru, Rh or Ir; R4 = 6-12C aryl, optionally substituted by 1-8C alkyl, benzyl or phenyl, or cyclopentadienyl optionally substituted by up to 5 groups or indenyl; and n = 1 or 2.

METHOD FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES THROUGH AZIDES

The present invention is directed to processes for the preparation of a tricyclic amino-alcohol derivative useful for treating and preventing diabetes, obesity, hyperlipidemia and the like, which compound is represented by the formula (1): wherein R1 represents a lower alkyl group or a benzyl group; *1 represents an asymmetric carbon atom; R2 represents a hydrogen atom, a halogen atom or a hydroxyl group; and A represents one of the following groups: wherein X represents NH, O or S; R5 represents a hydrogen atom, a hydroxyl group, an amino group or an acetylamino group; and *2 represents an asymmetric carbon atom when R5 is not a hydrogen atom. The processes of the present invention proceed via azide derivatives and are convenient, practical preparing processes with low cost which comprise a small number of steps with good industrial work efficiency.

Chemistry of opium alkaloids, 45. Improvements in the total synthesis of morphine

The chiral 1,2,3,4-tetrahydroisoquinoline intermediates in the Price and Beyerman routes to morphine, (+)-(R)-1-(3-hydroxy-4-methoxybenzyl)-6-methoxy- 1,2,3,4-tetrahydroisoquinoline (6) and (+)-(R)-1-(3,5-dibenzyloxy-4- methoxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (5), were prepared in high ee by ruthenium-catalyzed asymmetric transfer hydrogenation of the corresponding imine precursors (Noyori method). The yield of the key raw material in the Beyerman route, 3,5-dibenzyloxy-4-methoxyphenylacetric acid (1), starting from gallic acid methyl ester (7) was improved by a factor of 5 over previously described syntheses. Key steps in the new procedure are the selective formation of methyl 3,5-dihydroxy-4-methoxybenzoate (9) via the 3,5-diacetate and an improved benzylation of the hydroxyl groups in 9.